Historical Valuation
Terns Pharmaceuticals Inc (TERN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.27. The fair price of Terns Pharmaceuticals Inc (TERN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：35.48
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Terns Pharmaceuticals Inc (TERN) has a current Price-to-Book (P/B) ratio of 12.36. Compared to its 3-year average P/B ratio of 2.15 , the current P/B ratio is approximately 474.18% higher. Relative to its 5-year average P/B ratio of 1.72, the current P/B ratio is about 618.63% higher. Terns Pharmaceuticals Inc (TERN) has a Forward Free Cash Flow (FCF) yield of approximately -1.78%. Compared to its 3-year average FCF yield of -15.26%, the current FCF yield is approximately -88.33% lower. Relative to its 5-year average FCF yield of -21.64% , the current FCF yield is about -91.77% lower.
P/B
Median3y
2.15
Median5y
1.72
FCF Yield
Median3y
-15.26
Median5y
-21.64
Competitors Valuation Multiple
AI Analysis for TERN
The average P/S ratio for TERN competitors is 91.21, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TERN
1Y
3Y
5Y
Market capitalization of TERN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TERN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TERN currently overvalued or undervalued?
Terns Pharmaceuticals Inc (TERN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.27. The fair price of Terns Pharmaceuticals Inc (TERN) is between NaN to NaN according to relative valuation methord.
What is Terns Pharmaceuticals Inc (TERN) fair value?
TERN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Terns Pharmaceuticals Inc (TERN) is between NaN to NaN according to relative valuation methord.
How does TERN's valuation metrics compare to the industry average?
The average P/S ratio for TERN's competitors is 91.21, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Terns Pharmaceuticals Inc (TERN) as of Jan 10 2026?
As of Jan 10 2026, Terns Pharmaceuticals Inc (TERN) has a P/B ratio of 12.36. This indicates that the market values TERN at 12.36 times its book value.
What is the current FCF Yield for Terns Pharmaceuticals Inc (TERN) as of Jan 10 2026?
As of Jan 10 2026, Terns Pharmaceuticals Inc (TERN) has a FCF Yield of -1.78%. This means that for every dollar of Terns Pharmaceuticals Inc’s market capitalization, the company generates -1.78 cents in free cash flow.
What is the current Forward P/E ratio for Terns Pharmaceuticals Inc (TERN) as of Jan 10 2026?
As of Jan 10 2026, Terns Pharmaceuticals Inc (TERN) has a Forward P/E ratio of -31.32. This means the market is willing to pay $-31.32 for every dollar of Terns Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Terns Pharmaceuticals Inc (TERN) as of Jan 10 2026?
As of Jan 10 2026, Terns Pharmaceuticals Inc (TERN) has a Forward P/S ratio of 0.00. This means the market is valuing TERN at $0.00 for every dollar of expected revenue over the next 12 months.